Literature DB >> 27716588

A new integrated strategy for direct current cardioversion in non-valvular atrial fibrillation patients using short term rivaroxaban administration: The MonaldiVert real life experience.

Vincenzo Russo1, Lucia Di Napoli2, Valter Bianchi2, Vincenzo Tavoletta2, Stefano De Vivo2, Ciro Cavallaro2, Filipo Vecchione2, Anna Rago3, Berardo Sarubbi3, Paolo Calabrò3, Gerardo Nigro2, Antonio D'Onofrio2.   

Abstract

Entities:  

Keywords:  Atrial fibrillation; Cardioversion; Real life; Rivaroxaban; Transesophageal echocardiography; Trombus

Mesh：

Substances：

Year:  2016        PMID： 27716588     DOI： 10.1016/j.ijcard.2016.09.022

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN： 0167-5273            Impact factor:   4.164


× No keyword cloud information.
  11 in total

1.  Efficacy and safety of dabigatran in patients with atrial fibrillation scheduled for transoesophageal echocardiogram-guided direct electrical current cardioversion: a prospective propensity score-matched cohort study.

Authors:  Vincenzo Russo; Anna Rago; Andrea Antonio Papa; Antonio D'Onofrio; Paolo Golino; Gerardo Nigro
Journal:  J Thromb Thrombolysis       Date:  2018-02       Impact factor: 2.300

Review 2.  Efficacy and safety of the target-specific oral anticoagulants for stroke prevention in atrial fibrillation: the real-life evidence.

Authors:  Vincenzo Russo; Anna Rago; Riccardo Proietti; Federica Di Meo; Andrea Antonio Papa; Paolo Calabrò; Antonio D'Onofrio; Gerardo Nigro; Ahmed AlTurki
Journal:  Ther Adv Drug Saf       Date:  2016-10-24

3.  Complete resolution of left atrial appendage thrombosis with oral dabigatran etexilate in a patient with Myotonic Dystrophy type 1 and atrial fibrillation.

Authors:  Anna Rago; Andrea Antonio Papa; Giulia Arena; Marco Mosella; Antonio Cassese; Alberto Palladino; Paolo Golino
Journal:  Acta Myol       Date:  2017-12-01

Review 4.  Use of Direct Oral Anticoagulants Among Patients Undergoing Cardioversion: The Importance of Timing Before Cardioversion.

Authors:  Bruce A Warden; John MacKay; Melika Jafari; Alana Willman; Eric C Stecker
Journal:  J Am Heart Assoc       Date:  2018-11-20       Impact factor: 5.501

5.  Myotonic dystrophy type 1 and pulmonary embolism: successful thrombus resolution with dabigatran etexilate therapy.

Authors:  Emanuele Gallinoro; Andrea Antonio Papa; Anna Rago; Simona Sperlongano; Antonio Cassese; Nadia Della Cioppa; Maria Cristina Giada Magliocca; Giovanni Cimmino; Paolo Golino
Journal:  Acta Myol       Date:  2018-09-01

6.  Safety and Efficacy of Triple Antithrombotic Therapy with Dabigatran versus Vitamin K Antagonist in Atrial Fibrillation Patients: A Pilot Study.

Authors:  Vincenzo Russo; Anna Rago; Riccardo Proietti; Emilio Attena; Carmen Rainone; Mario Crisci; Andrea Antonio Papa; Paolo Calabrò; Antonio D'Onofrio; Paolo Golino; Gerardo Nigro
Journal:  Biomed Res Int       Date:  2019-02-13       Impact factor: 3.411

Review 7.  Diagnosis and Management of Left Atrium Appendage Thrombosis in Atrial Fibrillation Patients Undergoing Cardioversion.

Authors:  Enrico Melillo; Giuseppe Palmiero; Adele Ferro; Paola Elvira Mocavero; Vittorio Monda; Luigi Ascione
Journal:  Medicina (Kaunas)       Date:  2019-08-21       Impact factor: 2.430

8.  Stroke, Dementia, and Atrial Fibrillation: From Pathophysiologic Association to Pharmacological Implications.

Authors:  Vincenzo Russo; Riccardo Vio; Riccardo Proietti
Journal:  Medicina (Kaunas)       Date:  2020-05-10       Impact factor: 2.430

9.  The CHA₂DS₂-VASc Score Predicts Major Bleeding in Non-Valvular Atrial Fibrillation Patients Who Take Oral Anticoagulants.

Authors:  Kuang-Tso Lee; Shang-Hung Chang; Yung-Hsin Yeh; Hui-Tzu Tu; Yi-Hsin Chan; Chi-Tai Kuo; Lai-Chu See
Journal:  J Clin Med       Date:  2018-10-09       Impact factor: 4.241

Review 10.  Atrial Fibrillation and Stroke. A Review on the Use of Vitamin K Antagonists and Novel Oral Anticoagulants.

Authors:  Alfredo Caturano; Raffaele Galiero; Pia Clara Pafundi
Journal:  Medicina (Kaunas)       Date:  2019-09-20       Impact factor: 2.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.